Zynex, Inc. Aktie News

Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard talked with Proactive about the company's recent FDA submission for a new non-invasive pulse oximeter. The device, according to Sandgaard, offers improved accuracy in measuring oxygen levels, particularly for individuals with darker skin tones or conditions like carbon monoxide poisoning.

Investors can contact the law firm at no cost to learn more about recovering their losses

NEW YORK , May 19, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the "Class Period"), of the important May 19, 2025 lead plaintiff deadline. So What: If you purchased Zynex securities during the Class Period you may be entitled to compen...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025. Zynex is a medical device manufacturer. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allega...

NEW YORK , May 14, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the "Class Period"), of the important May 19, 2025 lead plaintiff deadline. So What: If you purchased Zynex securities during the Class Period you may be entitled to compen...

SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- A class-action lawsuit has been filed against Zynex, Inc. (NASDAQ: ZYXI), a medical device manufacturer specializing in electrotherapy devices, alleging that the company and certain of its top executives misled investors by overstating revenue through the practice of shipping excessive and unnecessary supplies to patients.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zynex To Contact Him Directly To Discuss Their Options